Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Diabetes Care 30:S200-S205, 2007
DOI: 10.2337/dc07-s216
© 2007 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kjos, S. L.
Right arrow Articles by Schaefer-Graf, U. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kjos, S. L.
Right arrow Articles by Schaefer-Graf, U. M.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Article

Modified Therapy for Gestational Diabetes Using High-Risk and Low-Risk Fetal Abdominal Circumference Growth to Select Strict Versus Relaxed Maternal Glycemic Targets

Siri L. Kjos, MD1 and Ute M. Schaefer-Graf, MD, PHD2

1 Department of Obstetrics and Gynecology, University of California, Los Angeles, Harbor UCLA Medical Center, Torrance, California
2 Department of Obstetrics, Vivantes, Berlin, Germany

Address correspondence and reprint requests to Siri Linda Kjos, MD, Department of Obstetrics and Gynecology, Harbor UCLA Medical Center, 1000 West Carson St., Box 3A, Torrance, CA 90509. E-mail: skjos@obgyn.humc.edu

Abbreviations: AC, abdominal circumference • GDM, gestational diabetes mellitus • LGA, large-for-gestational-age • SGA, small-for-gestational-age

The first 300 words of the full text of this article appear below.


    INTRODUCTION
 
The traditional treatment goal for gestational diabetes mellitus (GDM) has been to achieve "normal" range values for maternal glucose by diet and or insulin therapy, adapting a strategy successful in treating pregestational diabetes during pregnancy. Intensive insulin therapy to achieve strict euglycemia in GDM pregnancies has improved perinatal morbidity; however, it has not eliminated the excess rate of macrosomia compared with the reference populations (1). Increasing evidence suggests that disturbances in the intrauterine metabolic environment produced by GDM appear to increase the risk in offspring for obesity and diabetes. The obesity risk in early childhood in offspring born to mothers with GDM has been correlated with the birth weight and parental obesity, and those children who were large-for-gestational-age (LGA) at birth had obesity rates close to 40% compared with 25% in those born with normal weight (2). Studies that have attempted to reduce macrosomia rates by setting very strict glycemic targets during pregnancy have required insulin therapy in two-thirds of the women (3). However, only a minority of offspring of GDM mothers appear to be at risk for fetal overgrowth and newborn morbidity, even when GDM is untreated in blinded controlled trials (4,5). The Toronto Tri-Hospital Gestational Diabetes Project demonstrated a modest association of newborn morbidity with antenatal maternal glucose concentrations, adjusting for other risk factors (6). However, no threshold values that would suggest treatment were found.

These facts led Buchanan et al. (7) to advocate using fetal ultrasound measurements of growth in addition to maternal glycemia to identify which fetuses in utero are at increased and decreased risk for complications. This approach relaxes glycemic targets in women whose fetuses are at low risk for LGA growth and intensifies therapy by using stricter glycemic targets for . . . [Full Text of this Article]


    FETAL GROWTH MEASUREMENTS
 
Amniotic fluid insulin levels
Fetal abdominal circumference measurements

    RANDOMIZED INTERVENTION TRIALS UTILIZING FETAL ABDOMINAL CIRCUMFERENCE—
 

    SUMMARY—
 

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
U. M. Schaefer-Graf, K. Graf, I. Kulbacka, S. L. Kjos, J. Dudenhausen, K. Vetter, and E. Herrera
Maternal Lipids as Strong Determinants of Fetal Environment and Growth in Pregnancies With Gestational Diabetes Mellitus
Diabetes Care, September 1, 2008; 31(9): 1858 - 1863.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.